These types of TIMEs are associated with or without PD-L1 expression, which further demonstrates the limitations of using PD-L1 expression alone to select patients for anti-PD-(L)1 ICIs and a need for treatment strategies to augment tumor response to ICIs in cancers with an unresponsive TIME. The gene discussed is CD274; the disease is neoplasm.